Mixed Results With Afinitor in Advanced Breast Cancer

December 15, 2014 7:00 PM

16 0

SAN ANTONIO -- First-line treatment with everolimus (Afinitor), trastuzumab (Herceptin), and paclitaxel (Taxol) didn't improve survival in most women with advanced breast cancer, but a small subset of patients did see some benefit, researchers reported here.

In the BOLERO-1 trial for the co-primary endpoint of progression-free survival (PFS), women with HER2-positive disease treated with the addition of everolimus achieved a PFS of 14.95 months compared with 14.49 months for those who received trastuzumab, paclitaxel, and placebo (P=0.1166), reported Sa...

Read more

To category page